82 reports

Revenue(inUSDbillion) ## ##. ## ##. ## ##. ## ##. ## ##. ## ## ## ## ## ## 2015 2016 2017 2018 2023 Year In-vitro Diagnostics Market: Revenue in USD billion, by Application, Cardiology, United States, 2018-2023 ## ##. ##. ## AUTOIMMUNE DISEASES The In-vitro diagnostics market for

  • HIV AIDS
  • North America
  • United States
  • Becton Property Group
  • Bio-Rad Laboratories, Inc.
  • OF CONTENTS

In December 2017, the FDA approved Bristol-Myers Squibb' s PD-## inhibitor Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

  • HIV AIDS
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

The offers a wide range of devices and kits for autoimmune diseases worldwide.

  • Endoscope
  • Endoscopic Device
  • World
  • Forecast
  • Smith & Nephew Plc

Kaposi sarcoma induced due to HIV/ AIDS is one of the most common causes of the disease and acts as a major driver for the market.

  • HIV AIDS
  • Forecast
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • East Asia
  • Japan
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • Brazil
  • South America
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • Latin America
  • Mexico
  • North America

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • Australasia
  • Australia
  • Oceania

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • China
  • East Asia
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • India
  • South Asia
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • Italy
  • Southern Europe
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • Eastern Europe
  • Russia
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • East Asia
  • South Korea
  • Forecast

THE DISEASED POPULATION IS THE POPULATION SUFFERING FROM A PARTICULAR DISEASE OR CONDITION.

  • Endoscope
  • HIV AIDS
  • Southern Europe
  • Spain
  • Forecast
  • Identifying factors impacting market growth
  • EMEA - Market size and forecast 2017-2022

Some of the most common ear disorders affecting a large group of population (children and aged people) include otitis media, external ear infections, cerumen, and autoimmune ear disease.

  • Endoscope
  • Endoscopic Device
  • World
  • Forecast
  • GLOBAL ANTIVIRAL DRUGS MARKET SEGMENTATION BY THERAPIES

OTHER CAUSES INCLUDE HEAVY CONSUMPTION OF ALCOHOL, TOXINS, MEDICATIONS, AND OTHER INFECTIONS SUCH AS HIV AND AUTOIMMUNE DISEASES.

  • HIV AIDS
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.

The drug was one of the major contributors to the company' s revenue in 2014 and accounted for a major portion of overall revenue of the company' s infectious disease portfolio.

  • HIV AIDS
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson

MED-## is under development for treatment of autoimmune diseases such as multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and muscular dystrophy, osteoarthritis pain, visceral pain, neuropathic pain, transplantation and type-## diabetes.

  • HIV AIDS
  • Therapy
  • World
  • Supply
  • Medestea

" Cancer isn' t a one-size-fits all disease.

  • Cancer
  • Cell Therapy
  • HIV AIDS
  • Therapy
  • United States

THE COMPANY PROVIDES A RANGE OF PRODUCTS TO TREAT NEUROLOGICAL DISORDERS, AUTOIMMUNE DISEASES AND CANCER.

  • HIV AIDS
  • Canada
  • North America
  • United States
  • Mylan Inc.

TNF plays an important role in the development of rheumatoid arthritis (RA) and other autoimmune diseases.

  • HIV AIDS
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited
  • PERKINELMER

IT IS THE WORLD LEADER IN IN VITRO DIAGNOSTICS AND MEDICINES FOR CANCER AND TRANSPLANTATION; IT IS ALSO ACTIVE IN SEVERAL OTHER MAJOR THERAPEUTIC AREAS INCLUDING AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, VIROLOGY, METABOLIC DISORDERS AND DISEASES OF THE CENTRAL NE

  • HIV AIDS
  • China
  • Abbott Laboratories, Inc.
  • Immucor, Inc.
  • Roche Group
  • In Vitro Diagnostics Market: Market Share (%), by Application Type, Global, 2017
  • IN VITRO DIAGNOSTICS MARKET: REVENUE IN USD MILLION, BY APPLICATION, GLOBAL, 2015-2023

In-vitro diagnostics (IVD) are the medical devices and consumables are utilized to perform in-vitro tests on various biological samples. In-vitro diagnostics are used for diagnosis of various medical conditions. The global in-vitro diagnostics market is expected to register a CAGR of 5.5% during the forecast period of 2018–2023. Advanced...

  • HIV AIDS
  • Laboratory
  • World
  • Market Size
  • Siemens AG
  • PIPELINE BY CHEMOCENTRYX INC, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2018 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the...

  • HIV AIDS
  • United States
  • Company
  • Product Initiative
  • CytoDyn Inc.
  • PIPELINE BY CHEMOCENTRYX INC, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..1), H2 2017

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2017 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies...

  • Chemokine
  • HIV AIDS
  • Therapy
  • United States
  • Product Initiative
  • BECKMAN COULTER (U.S.)

The IVD market in BRIC is expected to reach USD 15.71 billion by 2022 from USD 10.60 billion in 2017, at a CAGR of 8.2%. The key factors driving the growth of the market are growing patient awareness of personalized medicine, increasing prevalence of lifestyle and chronic diseases, growth in the number of private diagnostic centers, and improving...

  • HIV AIDS
  • Medical Device
  • North America
  • United States
  • Market Size
  • VRC-01 - DRUG PROFILE
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones

Lupuzor is the Company' s lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

  • HIV AIDS
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • TRANSFER MEMBRANE MARKET, BY APPLICATION (2018 VS. 2023)
  • WESTERN BLOTTING SEGMENT TO DOMINATE THE MARKET IN 2018

Proteomic research has various biomedical applications such as biomarker discovery, cancer research, disease diagnosis, and autoimmune disease treatment.

  • HIV AIDS
  • North America
  • United States
  • Forecast
  • Merck & Co., Inc.
  • Do not have: cervical esophageal carcinoma, known or suspected autoimmune disease, HIV, or AIDS

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016’, provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics....

  • Cancer Immunotherapy
  • HIV AIDS
  • Oncology
  • Therapy
  • Merck & Co., Inc.
  • Source: Press Releases
  • Grifols

The blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%. The global blood screening market is categorized based on technology, product & service, end user, and region. The technology segment includes nucleic acid tests (NAT), enzyme-linked immunosorbent assay (ELISA), rapid...

  • HIV AIDS
  • North America
  • United States
  • Market Size
  • Roche Group